This company has been acquired
La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
LogicBio Therapeutics Gestione
Gestione criteri di controllo 1/4
Informazioni chiave
Fred Chereau
Amministratore delegato
US$2.2m
Compenso totale
| Percentuale dello stipendio del CEO | 24.3% |
| Mandato del CEO | 6.6yrs |
| Proprietà del CEO | 0.8% |
| Durata media del management | 1.8yrs |
| Durata media del Consiglio di amministrazione | 3.4yrs |
Aggiornamenti recenti sulla gestione
Recent updates
LogicBio jumps 648% on buyout deal with AstraZeneca unit Alexion
Oct 03Bullish: Analysts Just Made A Notable Upgrade To Their LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Forecasts
Aug 20
LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Just Reported Second-Quarter Earnings And Analysts Are Lifting Their Estimates
Aug 18LogicBio GAAP EPS of -$0.15, revenue of $3.2M
Aug 15Is LogicBio Therapeutics (NASDAQ:LOGC) Weighed On By Its Debt Load?
Jan 11Does LogicBio Therapeutics (NASDAQ:LOGC) Have A Healthy Balance Sheet?
Aug 18LogicBio EPS misses by $0.06, beats on revenue
May 10LogicBio announces agreements with CANbridge Pharma and Daiichi Sankyo
Apr 27Is LogicBio Therapeutics (NASDAQ:LOGC) Using Debt Sensibly?
Apr 12Is LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Popular Amongst Insiders?
Mar 08The LogicBio Therapeutics (NASDAQ:LOGC) Share Price Has Gained 12% And Shareholders Are Hoping For More
Jan 15LogicBio extends collaboration with Children's Medical Research Institute
Jan 07LogicBio Therapeutics names new CFO
Dec 22Looking In On LogicBio
Nov 17LogicBio reports Q3 results
Nov 09Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Guadagni aziendali |
|---|---|---|---|
| Sep 30 2022 | n/a | n/a | -US$27m |
| Jun 30 2022 | n/a | n/a | -US$31m |
| Mar 31 2022 | n/a | n/a | -US$36m |
| Dec 31 2021 | US$2m | US$543k | -US$40m |
| Sep 30 2021 | n/a | n/a | -US$38m |
| Jun 30 2021 | n/a | n/a | -US$36m |
| Mar 31 2021 | n/a | n/a | -US$33m |
| Dec 31 2020 | US$2m | US$479k | -US$33m |
| Sep 30 2020 | n/a | n/a | -US$37m |
| Jun 30 2020 | n/a | n/a | -US$40m |
| Mar 31 2020 | n/a | n/a | -US$42m |
| Dec 31 2019 | US$633k | US$510k | -US$40m |
| Sep 30 2019 | n/a | n/a | -US$32m |
| Jun 30 2019 | n/a | n/a | -US$29m |
| Mar 31 2019 | n/a | n/a | -US$23m |
| Dec 31 2018 | US$2m | US$411k | -US$18m |
| Sep 30 2018 | n/a | n/a | -US$18m |
| Jun 30 2018 | n/a | n/a | -US$11m |
| Mar 31 2018 | n/a | n/a | -US$9m |
| Dec 31 2017 | US$779k | US$385k | -US$8m |
Compensazione vs Mercato: Fred's total compensation ($USD2.23M) is above average for companies of similar size in the US market ($USD750.11K).
Compensazione vs guadagni: Fred's compensation has increased whilst the company is unprofitable.
AMMINISTRATORE DELEGATO
Fred Chereau (55 yo)
6.6yrs
Mandato
US$2,228,208
Compensazione
Mr. Frederic Chereau, M.B.A., also known as Fred, is the Chairman of the Board of Coave Therapeutics since October 2022 and has been its Independent Non-Executive Director since October 2021. He has execut...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| President | 6.6yrs | US$2.23m | 0.77% $ 525.4k | |
| Co-Founder | no data | US$156.64k | 2.38% $ 1.6m | |
| Chief Medical Officer | 2.4yrs | US$1.54m | 0.010% $ 6.9k | |
| Co-Founder & Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Co-Founder | 8.3yrs | Nessun dato | Nessun dato | |
| Interim CFO | less than a year | Nessun dato | Nessun dato | |
| Global VP & Head of Technology Development | 3.6yrs | Nessun dato | Nessun dato | |
| Chief Scientific Officer | 2yrs | US$1.34m | Nessun dato | |
| General Counsel & Corporate Secretary | 1.5yrs | Nessun dato | Nessun dato | |
| VP & Head of Human Resources | 1.2yrs | Nessun dato | Nessun dato | |
| Senior Vice President of Strategy & Portfolio Management | 1.4yrs | Nessun dato | Nessun dato | |
| Chief Business Officer | 1.3yrs | Nessun dato | Nessun dato |
1.8yrs
Durata media
55yo
Età media
Gestione esperta: LOGC's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| President | no data | US$2.23m | 0.77% $ 525.4k | |
| Co-Founder | 6.8yrs | US$156.64k | 2.38% $ 1.6m | |
| Co-Founder & Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Independent Director | 4.2yrs | US$87.39k | 0.0095% $ 6.5k | |
| Independent Chairman of the Board | 4.1yrs | US$113.64k | 0.012% $ 8.1k | |
| Independent Director | 2.7yrs | US$82.02k | 0.0089% $ 6.0k | |
| Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Independent Director | 6.8yrs | US$81.14k | 0.068% $ 46.2k | |
| Independent Director | 1.9yrs | US$76.77k | 0% $ 0 | |
| Independent Director | 1.9yrs | US$79.64k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Independent Director | less than a year | US$40.31k | Nessun dato |
3.4yrs
Durata media
58yo
Età media
Consiglio di amministrazione esperto: LOGC's board of directors are considered experienced (3.4 years average tenure).